Article
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Cancer - 1 Feb 2021
Janku Filip, Sakamuri Divya, Kato Shumei, Huang Helen J, Call S Greg, Naing Aung, Holley Veronica R, Patel Sapna P, Amaria Rodabe N, Falchook Gerald S, Piha-Paul Sarina A, Zinner Ralph G, Tsimberidou Apostolia M, Hong David S, Meric-Bernstam Funda
Abstract excerpt
BACKGROUND: BRAF inhibitors are effective in melanoma and other cancers with BRAF mutations; however, patients ultimately develop therapeutic resistance through the activation of alternative signaling pathways such as RAF/RAS or MET. The authors hypothesized that combining the BRAF inhibitor vemurafenib with either the multikinase inhibitor sorafenib or the MET inhibitor crizotinib could overcome therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.